Literature DB >> 17072524

Health-related quality of life after permanent interstitial brachytherapy for prostate cancer: correlation with postimplant CT scan parameters.

Michael Pinkawa1, Karin Fischedick, Marc D Piroth, Bernd Gagel, Holger Borchers, Gerhard Jakse, Michael J Eble.   

Abstract

PURPOSE: To determine dosimetric risk factors for increased toxicity after permanent interstitial brachytherapy for prostate cancer. PATIENTS AND METHODS: Quality of life questionnaires (Expanded Prostate Cancer Index Composite) of 60 and 56 patients were analyzed after a median posttreatment time of 6 weeks (A-acute) and 16 months (L-late). The corresponding CT scans were performed 30 days after the implant. The prostate, rectal wall, and base of seminal vesicles were contoured. Prostate volume, number of seeds and needles as well as dosimetric parameters were correlated with the morbidity scores.
RESULTS: For a prostate volume of 38 +/- 12 cm(3) (mean +/- standard deviation), 54 +/- 7 (125)I sources (Rapid Strands), activity of 22.6 +/- 3.0 MBq [0.61 +/- 0.08 mCi]) were implanted using 20 +/- 6 needles. Improved late urinary function scores resulted from a higher number of sources per cm(3) (> or = 1.35). A prostate D(90) < 170 Gy (A)/< 185 Gy (L) and base of seminal vesicle D(10) < 190 Gy (A and L) were associated with higher urinary function scores. Late rectal function scores were significantly higher for patients with a prostate V(200) < 50% and V(150) < 75%. Patients with a prostate volume < 40 cm(3) reached better sexual function scores (A and L). A higher number of needles per cm(3) (> or = 0.5) resulted in improved late urinary, bowel and sexual function scores.
CONCLUSION: Quality of life after a permanent implant can be improved by using an adequate amount of sources and needles. With an increasing number of seeds per cm(3), dose homogeneity is improving. A prostate D(90) < 170 Gy and a base of seminal vesicle D(10) < 190 Gy (as an indicator of the dose to the bladder neck and urethral sphincter) can be recommended to maintain a satisfactory urinary function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072524     DOI: 10.1007/s00066-006-1530-z

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  12 in total

1.  Stereotactic interstitial radiosurgery for intracranial Rosai-Dorfman disease. A novel therapeutic approach.

Authors:  Faycal El Majdoub; Anna Brunn; Frank Berthold; Volker Sturm; Mohammad Maarouf
Journal:  Strahlenther Onkol       Date:  2009-02-25       Impact factor: 3.621

2.  Reductions in prostatic doses are associated with less acute morbidity in patients undergoing Pd-103 brachytherapy: Substantiation of the rationale for focal therapy.

Authors:  Adam Ferro; Hee Joon Bae; Gayane Yenokyan; Yi Le; Todd McNutt; Omar Mian; Carol Gergis; Chloe Haviland; Theodore L DeWeese; Daniel Y Song
Journal:  Brachytherapy       Date:  2017-11-23       Impact factor: 2.362

3.  Impact of learning curve and technical changes on dosimetry in low-dose brachytherapy for prostate cancer.

Authors:  E Le Fur; J P Malhaire; D Baverez; F Delage; M A Perrouin-Verbe; F Schlurmann; S Guerif; G Fournier; O Pradier; A Valeri
Journal:  Strahlenther Onkol       Date:  2012-11-11       Impact factor: 3.621

4.  Quality of life two years after radical prostatectomy, prostate brachytherapy or external beam radiotherapy for clinically localised prostate cancer: the Catalan Institute of Oncology/Bellvitge Hospital experience.

Authors:  F Guedea; M Ferrer; J Pera; F Aguiló; A Boladeras; J F Suárez; O Cunillera; F Ferrer; Y Pardo; E Martínez; M Ventura
Journal:  Clin Transl Oncol       Date:  2009-07       Impact factor: 3.405

5.  An MRI-based dose--reponse analysis of urinary sphincter dose and urinary morbidity after brachytherapy for prostate cancer in a phase II prospective trial.

Authors:  Steven P Register; Rajat J Kudchadker; Lawrence B Levy; David A Swanson; Thomas J Pugh; Teresa L Bruno; Steven J Frank
Journal:  Brachytherapy       Date:  2013-03-01       Impact factor: 2.362

6.  Neoadjuvant hormonal therapy and external-beam radiotherapy versus external-beam irradiation alone for prostate cancer. A quality-of-life analysis.

Authors:  Michael Pinkawa; Marc D Piroth; Branka Asadpour; Bernd Gagel; Karin Fischedick; Jaroslav Siluschek; Mareike Kehl; Barbara Krenkel; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2009-02-25       Impact factor: 3.621

7.  Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: implications for establishing new dose constraints for treatment planning.

Authors:  Lara Hathout; Michael R Folkert; Marisa A Kollmeier; Yoshiya Yamada; Gil'ad N Cohen; Michael J Zelefsky
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-10-01       Impact factor: 7.038

8.  A Population-based Statistical Model for Investigating Heterogeneous Intraprostatic Sensitivity to Radiation Toxicity After 125I Seed Implantation.

Authors:  Kazuma Kobayashi; Naoya Murakami; Kana Takahashi; Koji Inaba; Hiroshi Igaki; Ryuji Hamamoto; Jun Itami
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

9.  Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment.

Authors:  Michael Pinkawa; Karin Fischedick; Bernd Gagel; Marc D Piroth; Branka Asadpour; Jens Klotz; Holger Borchers; Gerhard Jakse; Michael J Eble
Journal:  BMC Cancer       Date:  2009-08-24       Impact factor: 4.430

10.  Rosai-Dorfman disease mimicking images of meningiomas: Two case reports and literature review.

Authors:  Rafael Trindade Tatit; Paulo Eduardo Albuquerque Zito Raffa; Giovana Cassia de Almeida Motta; André Alexandre Bocchi; Júlia Loripe Guimaraes; Paulo Roberto Franceschini; Paulo Henrique Pires de Aguiar
Journal:  Surg Neurol Int       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.